Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2009 Dec;66(12):1537-44.
doi: 10.1001/archneurol.2009.285.

High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types

Affiliations
Comparative Study

High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types

Victor L Villemagne et al. Arch Neurol. 2009 Dec.

Abstract

Background: Supported by compelling genetic data regarding early-onset familial Alzheimer disease (AD), the amyloid beta-peptide (Abeta)-centric theory holds that Abeta is involved in the pathogenesis of sporadic AD. Mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) genes lead to increased Abeta levels before symptoms arise.

Objectives: To evaluate the pattern of Pittsburgh Compound B (PiB) retention in subjects with different autosomal dominant mutations associated with familial AD vs that in healthy age-matched control subjects and subjects with probable sporadic AD, to correlate Abeta burden as measured by PiB with available clinical and cognitive data, and to compare the regional brain patterns of PiB retention and fluorodeoxyglucose F 18 (FDG) uptake.

Design: Correlation analysis of positron emission tomography (PET) imaging studies.

Setting: Academic research.

Participants: Seven PSEN1 mutation carriers and 1 APP mutation carrier underwent PiB and FDG PET imaging. Amyloid beta-peptide burden and FDG uptake were established using standardized uptake values normalized to pons.

Main outcome measure: Primary outcomes were PET results, which were compared with those of a well-characterized cohort of 30 healthy control subjects and 30 subjects with probable sporadic AD.

Results: All mutation carriers had high PiB retention in the striatum, with some also having cortical PiB retention in ventrofrontal and posterior cingulate/precuneus areas. The striatal pattern of PiB retention was similar in the PSEN1 and APP mutation carriers. Neither striatal nor cortical Abeta burden was related to cognitive status.

Conclusions: Consistent with previous studies, the pattern of Abeta deposition in familial AD differs from that in sporadic AD, with higher striatal and somewhat lower cortical PiB retention in familial AD. The pattern and degree of Abeta deposition were not associated with mutation type nor cognitive status.

PubMed Disclaimer

Similar articles

Cited by

  • When Does Alzheimer's Disease Really Start? The Role of Biomarkers.
    Lloret A, Esteve D, Lloret MA, Cervera-Ferri A, Lopez B, Nepomuceno M, Monllor P. Lloret A, et al. Int J Mol Sci. 2019 Nov 6;20(22):5536. doi: 10.3390/ijms20225536. Int J Mol Sci. 2019. PMID: 31698826 Free PMC article. Review.
  • PET staging of amyloidosis using striatum.
    Hanseeuw BJ, Betensky RA, Mormino EC, Schultz AP, Sepulcre J, Becker JA, Jacobs HIL, Buckley RF, LaPoint MR, Vannini P, Donovan NJ, Chhatwal JP, Marshall GA, Papp KV, Amariglio RE, Rentz DM, Sperling RA, Johnson KA; Alzheimer's Disease Neuroimaging Initiative; Harvard Aging Brain Study. Hanseeuw BJ, et al. Alzheimers Dement. 2018 Oct;14(10):1281-1292. doi: 10.1016/j.jalz.2018.04.011. Epub 2018 May 21. Alzheimers Dement. 2018. PMID: 29792874 Free PMC article.
  • Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.
    Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, Agarwal N, Mormino EC, O'Neil JP, Janabi M, Karydas A, Growdon ME, Jang JY, Huang EJ, Dearmond SJ, Trojanowski JQ, Grinberg LT, Gorno-Tempini ML, Seeley WW, Miller BL, Jagust WJ. Rabinovici GD, et al. Neurology. 2011 Dec 6;77(23):2034-42. doi: 10.1212/WNL.0b013e31823b9c5e. Epub 2011 Nov 30. Neurology. 2011. PMID: 22131541 Free PMC article.
  • Differential putaminal morphology in Huntington's disease, frontotemporal dementia and Alzheimer's disease.
    Looi JC, Rajagopalan P, Walterfang M, Madsen SK, Thompson PM, Macfarlane MD, Ching C, Chua P, Velakoulis D. Looi JC, et al. Aust N Z J Psychiatry. 2012 Dec;46(12):1145-58. doi: 10.1177/0004867412457224. Epub 2012 Sep 18. Aust N Z J Psychiatry. 2012. PMID: 22990433 Free PMC article.
  • Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.
    Yau WW, Tudorascu DL, McDade EM, Ikonomovic S, James JA, Minhas D, Mowrey W, Sheu LK, Snitz BE, Weissfeld L, Gianaros PJ, Aizenstein HJ, Price JC, Mathis CA, Lopez OL, Klunk WE. Yau WW, et al. Lancet Neurol. 2015 Aug;14(8):804-813. doi: 10.1016/S1474-4422(15)00135-0. Epub 2015 Jun 29. Lancet Neurol. 2015. PMID: 26139022 Free PMC article.

Publication types